Wellington Management Group LLP Raises Holdings in Glaukos Corporation $GKOS

Key Points

• Wellington Management Group LLP increased its stake in Glaukos Corporation by 6.1% during Q1, owning a total of 2,290,790 shares valued at approximately $225.46 million.
• Several hedge funds significantly raised their positions in Glaukos, with Whipplewood Advisors LLC increasing their stake by a staggering 3,957.1% in the first quarter.
• Glaukos recently reported earnings that surpassed expectations, with revenues of $124.12 million and earnings per share of (0.24), beating the consensus estimates.

Wellington Management Group LLP increased its stake in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 6.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,290,790 shares of the medical instruments supplier's stock after purchasing an additional 131,251 shares during the quarter. Wellington Management Group LLP owned 4.01% of Glaukos worth $225,460,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Versor Investments LP boosted its position in shares of Glaukos by 143.9% during the 1st quarter. Versor Investments LP now owns 13,272 shares of the medical instruments supplier's stock worth $1,306,000 after acquiring an additional 7,830 shares in the last quarter. Raymond James Financial Inc. boosted its position in shares of Glaukos by 14.4% during the 1st quarter. Raymond James Financial Inc. now owns 128,966 shares of the medical instruments supplier's stock worth $12,694,000 after acquiring an additional 16,195 shares in the last quarter. Sei Investments Co. boosted its position in shares of Glaukos by 19.7% during the 1st quarter. Sei Investments Co. now owns 106,135 shares of the medical instruments supplier's stock worth $10,446,000 after acquiring an additional 17,445 shares in the last quarter. Sit Investment Associates Inc. boosted its position in shares of Glaukos by 4.9% during the 1st quarter. Sit Investment Associates Inc. now owns 17,640 shares of the medical instruments supplier's stock worth $1,736,000 after acquiring an additional 825 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its position in shares of Glaukos by 174.9% during the 1st quarter. Russell Investments Group Ltd. now owns 38,393 shares of the medical instruments supplier's stock worth $3,779,000 after acquiring an additional 24,428 shares in the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Stock Performance

GKOS traded down $0.8950 on Monday, hitting $93.2550. 68,622 shares of the company traded hands, compared to its average volume of 947,224. The company has a 50 day moving average of $96.26 and a 200-day moving average of $100.70. The company has a quick ratio of 4.69, a current ratio of 5.51 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $5.35 billion, a PE ratio of -56.49 and a beta of 0.78. Glaukos Corporation has a 12-month low of $77.10 and a 12-month high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.02. The firm had revenue of $124.12 million during the quarter, compared to the consensus estimate of $115.49 million. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The firm's revenue was up 29.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.52) EPS. Glaukos has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Glaukos Corporation will post -1.08 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on GKOS. Stifel Nicolaus lowered their price objective on Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. Stephens lowered their price objective on Glaukos from $140.00 to $115.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. William Blair raised Glaukos to a "strong-buy" rating in a research report on Thursday, July 31st. Mizuho set a $130.00 price objective on Glaukos in a research report on Thursday, July 31st. Finally, BTIG Research reissued a "buy" rating on shares of Glaukos in a report on Monday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $127.42.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.